A rare case of strontium induced dermatitis in an osteoporotic patient taking an over-the-counter supplement: a case study

Bhalala Priyank Batukbhai; Rajbhandari Pranaya; Fenilkumar Nitinbhai Ribadiya; Henry Zaleski

doi:10.18203/2320-6012.ijrms20252422

Authors

Bhalala Priyank Batukbhai ASPIRE, Department of Internal Medicine, Grodno State Medical University, Grodno, Belarus
Rajbhandari Pranaya Department of Internal Medicine, Patan Academy of Health Sciences, Lalitpur, Nepal
Fenilkumar Nitinbhai Ribadiya ASPIRE, Department of Internal Medicine, Grodno State Medical University, Grodno, Belarus
Henry Zaleski Department of Internal Medicine, Houston Methodist Hospital, Houston, USA

DOI:

https://doi.org/10.18203/2320-6012.ijrms20252422

Keywords:

Strontim toxicity, Osteoporosis, Osteoporosis management, Strontium citrate

Abstract

Strontium ranelate, a strontium salt, is used in osteoporosis treatment due to its dual mechanism of promoting bone formation and inhibiting resorption. Although it is effective, strict monitoring is recommended because of it adverse reactions particularly related to cardiovascular and cutaneous adverse reactions. We report the case of a 71-year-old woman with a 20-year history of osteoporosis who developed progressive dermatitis and generalized pruritus over 1.5 years. Extensive dermatologic and rheumatologic evaluations, including skin biopsies, were inconclusive. Upon detailed history, the patient disclosed long-term use of an over-the-counter (OTC) vitamin supplement containing strontium citrate. Performed laboratory testing revealed significantly elevated serum strontium levels (124.2 ng/ml; reference: 8.3-34.3). After discontinuation of the supplement, her symptoms gradually resolved without specific treatment. This case highlights strontium toxicity manifesting as cutaneous symptoms, potentially caused by chronic ingestion of OTC strontium. While adverse effects of prescription strontium ranelate are documented, reports of toxicity from non-prescription strontium citrate are rare. The patient’s clinical improvement and declining strontium levels after supplement cessation strongly support the diagnosis. This is a rare and possibly novel case of cutaneous strontium toxicity linked to an OTC supplement. Clinicians should consider strontium toxicity in patients presenting with unexplained dermatitis and a history of osteoporosis, particularly when supplement use is identified. Greater awareness and regulation of strontium-containing OTC products are warranted.

Metrics

Metrics Loading ...

References

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis Prevention, Diagnosis, and Therapy. JAMA. 2001;285(6):785-95. DOI: https://doi.org/10.1001/jama.285.6.785

Marie PJ. Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporosis Int. 2005;16(1):S7-10. DOI: https://doi.org/10.1007/s00198-004-1753-8

O’Donnell S, Cranney A, Wells G, Adachi J, Reginster J. Strontium ranelate for preventing and treating postmenopausal osteoporosis. in Cochrane Database of Systematic Reviews (ed. O’Donnell, S.) (John Wiley and Sons, Ltd, Chichester, UK. 2006. DOI: https://doi.org/10.1002/14651858.CD005326.pub3

Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab. 2005;90(5):2816-22. DOI: https://doi.org/10.1210/jc.2004-1774

Deeks ED, Dhillon S. Strontium Ranelate. Drugs. 2010;70:733-59. DOI: https://doi.org/10.2165/10481900-000000000-00000

Jonville-Bera AP, Autret-Leca E. Ranélate de strontium (Protelos®): effets indésirables rapportés en France. Presse Med. 2011;40:e453-62. DOI: https://doi.org/10.1016/j.lpm.2011.07.010

di Meo N, Gubertini N, Crocè L, Tiribelli C, Trevisan G. DRESS syndrome with autoimmune hepatitis from strontium ranelate. Cutis. 2016;97:E22-6.

Brennan T, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol. 2009;157(7):1291-300. DOI: https://doi.org/10.1111/j.1476-5381.2009.00305.x

Coulombe J, Faure H, Robin B, Ruat M. In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem Biophys Res Commun. 2004;323(4):1184-90. DOI: https://doi.org/10.1016/j.bbrc.2004.08.209

Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol. 2007;74(3):438-47. DOI: https://doi.org/10.1016/j.bcp.2007.04.020

Zhu LL, Samir Z, Yuanzhen P, Hang Z, Moonga BS, Blesius A, et al. Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem Biophys Res Commun. 2007;355(2):307-11. DOI: https://doi.org/10.1016/j.bbrc.2007.01.120

Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, Cournarie F, Wattel A, Kamel S, et al. The Calcium-sensing Receptor Is Involved in Strontium Ranelate-induced Osteoclast Apoptosis. J Biological Chem. 2009;284(1):575-84. DOI: https://doi.org/10.1074/jbc.M801668200

Edvinsson L, Ikomi-Kumm J, Monti M. Effects of calcium entry blockers on human platelet metabolism measured by microcalorimetry. Hum Toxicol. 1989;8:131-3. DOI: https://doi.org/10.1177/096032718900800208

Przedlacki J. Strontium ranelate in post-menopausal osteoporosis. Endokrynol Pol. 2011;62(2):23-31.

Kolitz E, McKesey J, Kwan E, Gill JG, Mauskar M. Strontium citrate associated drug reaction with eosinophilia and systemic symptoms syndrome with granulomatous dermatitis. JAAD Case Rep. 2021;10:85-8. DOI: https://doi.org/10.1016/j.jdcr.2021.02.002

Fernando SL, Henderson CJ, O’Connor KS. Drug-Induced Hypersensitivity Syndrome with Superficial Granulomatous Dermatitis-A Novel Finding. Am J Dermatopathol. 2009;31(6):611-13. DOI: https://doi.org/10.1097/DAD.0b013e3181a18d64